Literature DB >> 11986285

Increased levels of soluble CD30 in plasma of patients with Plasmodium falciparum malaria.

Kåre Kemp1, Jørgen A L Kurtzhals, Bartholomew D Akanmori, Victoria Adabayeri, Bamenla Q Goka, Charlotte Behr, Lars Hviid.   

Abstract

Levels of soluble CD30 (sCD30) in serum were elevated in patients with Plasmodium falciparum malaria but showed decline following treatment. The levels of sCD30 in serum were correlated significantly with the expression of gamma interferon by peripheral T cells. These data suggest that CD30(+) cells are upregulated during a malaria attack and that they may play a regulating role at the site of inflammation.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11986285      PMCID： PMC119977          DOI： 10.1128/cdli.9.3.720-722.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  17 in total

Review 1.  Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases.

Authors:  R Gerli; C Lunardi; F Vinante; O Bistoni; G Pizzolo; C Pitzalis
Journal:  Trends Immunol       Date:  2001-02       Impact factor: 16.687

2.  Engagement of CD30 shapes the secretion of cytokines by human gamma delta T cells.

Authors:  P Biswas; P Rovere; C De Filippi; S Heltai; C Smith; L Dagna; G Poli; A A Manfredi; M Ferrarini
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

3.  Cytokine production and apoptosis among T cells from patients under treatment for Plasmodium falciparum malaria.

Authors:  K Kemp; B D Akanmori; V Adabayeri; B Q Goka; J A L Kurtzhals; C Behr; L Hviid
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

4.  Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians.

Authors:  R Gerli; D Monti; O Bistoni; A M Mazzone; G Peri; A Cossarizza; M Di Gioacchino; M E Cesarotti; A Doni; A Mantovani; C Franceschi; R Paganelli
Journal:  Mech Ageing Dev       Date:  2000-12-20       Impact factor: 5.432

5.  A new portable device for automatic controlled-gradient cryopreservation of blood mononuclear cells.

Authors:  L Hviid; G Albeck; B Hansen; T G Theander; A Talbot
Journal:  J Immunol Methods       Date:  1993-01-04       Impact factor: 2.303

6.  CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells.

Authors:  T M Ellis; P E Simms; D J Slivnick; H M Jäck; R I Fisher
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

7.  Identification of IFN-gamma-producing CD4+ T cells following PMA stimulation.

Authors:  K Kemp; H Bruunsgaard
Journal:  J Interferon Cytokine Res       Date:  2001-07       Impact factor: 2.607

8.  High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS.

Authors:  G Pizzolo; F Vinante; L Morosato; G Nadali; M Chilosi; G Gandini; A Sinicco; R Raiteri; G Semenzato; H Stein
Journal:  AIDS       Date:  1994-06       Impact factor: 4.177

9.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.

Authors:  C A Smith; H J Gruss; T Davis; D Anderson; T Farrah; E Baker; G R Sutherland; C I Brannan; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

10.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.

Authors:  H Dürkop; U Latza; M Hummel; F Eitelbach; B Seed; H Stein
Journal:  Cell       Date:  1992-02-07       Impact factor: 41.582
View more
  1 in total

1.  T cell subtypes and reciprocal inflammatory mediator expression differentiate P. falciparum memory recall responses in asymptomatic and symptomatic malaria patients in southeastern Haiti.

Authors:  Jason S Lehmann; Joseph J Campo; Micheline Cicéron; Christian P Raccurt; Jacques Boncy; Valery E M Beau De Rochars; Anthony P Cannella
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.